Featured Content

Winston, Wong, PharmD
President, W-Squared Group

Express Scripts to Calculate 'Blended' Drug Prices

(BioCentury) Nov 20, 2015 - Express Scripts Holding Co. CMO Steve Miller said the company will create a "blended price" for drugs as part of its new indication-based pricing scheme.

Commentary: The evaluation process by which ESI is going to establish the blended pricing is a new concept. While other value...

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

FDA Approves Empliciti, A New Immune-Stimulating Therapy To Treat Multiple Myeloma

(FDA.gov) Nov 30, 2015 - Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.
read press release »


View ALL News »

News Story Commentary By Academic and Community Oncologists

Express Scripts to Calculate 'Blended' Drug Prices (BioCentury)

The evaluation process by which ESI is going to establish the blended pricing is a new concept. While other value...posted by: Winston, Wong, PharmD

FDA Approves Portrazza To Treat Advanced Squamous Non-Small Cell Lung Cancer (FDA.gov)

Necitumumab is a treatment with significant side effects that improves survival by a median of less than two months....posted by: H. Jack West, MD

Doctors Call for Drug Advertising Ban in Position Reversal (Bloomberg)

As one who attended the HOD meeting the discussion on DTC advertising was lively. Both sides were heard. In...posted by: Thomas, Marsland, MD

Novartis Biosimilar Takes Aim At Amgen Drug Neulasta (Reuters)

Watching the impact of the Neupogen biosimilar and Granix is having on the market is interesting. Those who are...posted by: Winston, Wong, PharmD

Specialty Drugs Now Cost More Than the Median Household Income (Washington Post/Wonkblog)

This is an interesting way to put the high cost of specialty medications in perspective, and it is very effective....posted by: Winston, Wong, PharmD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

Seattle Genetics has 1 job posted.

Check out the OBR Job Board here.

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
AEZS +8.76%
KBIO +6.14%
CLBS +5.83%
ARGS -7.36%
KITE -6.76%
KPTI -6.63%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: November 30, 2015
Company: Bristol-Myers Squibb Co. / AbbVie
Product: Empliciti (elotuzumab)

Date: December 19, 2015
Company: Merck
Product: Keytruda® (pembrolizumab)

Date: December 24, 2015
Company: Merck
Product: Keytruda® (pembrolizumab)

See All OBR Radar items»